This clinical trial is focused on studying a condition called Myotonic Dystrophy Type 1, which is a genetic disorder that affects muscle function. The study is testing a new treatment called AOC 1001, which is given as a solution through an intravenous infusion. This means the treatment is delivered directly into the bloodstream through a vein. AOC 1001 is a special type of medication that combines a humanized antibody with a small piece of genetic material designed to target and reduce the effects of the disease.

The purpose of the study is to evaluate how effective AOC 1001 is in improving hand function in people with Myotonic Dystrophy Type 1. Participants in the study will receive either the AOC 1001 treatment or a placebo, which is a substance with no active medication. The study will last for a period of 54 weeks, during which participants will have regular visits to monitor their progress and assess any changes in their condition.

Throughout the study, researchers will focus on measuring changes in hand function, as well as other aspects of muscle strength and daily activities. The goal is to determine if AOC 1001 can help improve the quality of life for those living with Myotonic Dystrophy Type 1. Participants will be closely monitored to ensure their safety and to gather important information about the treatment’s effects.